Drugs Approved for Breast Cancer - NCI
Feb 24, 2025 · This page lists cancer drugs approved by the Food and Drug Administration (FDA) for breast cancer. The list includes generic names, brand names, and common drug …
New breast cancer drugs and combinations show promise | LBBC
Jun 4, 2025 · At this year’s American Society for Clinical Oncology annual meeting, researchers shared promising new treatment options for early- stage as well as advanced or metastatic …
Treatment of Breast Cancer | Breast Cancer | CDC - Centers for Disease …
Feb 22, 2024 · Treatment options Breast cancer is treated in several ways. It depends on the kind of breast cancer and how far it has spread. Surgery: Is an operation in which doctors cut out …
A review of FDA approved drugs and their formulations for the treatment …
Though the mortality rate of breast cancer has changed a little over the years, the survival rate, however, has also increased due to awareness campaigns, early detection programs, and …
FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2 ...
13 hours ago · Key Takeaways Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the FDA. Enhertu, a HER2-directed …
New breast cancer drug slashes risk of disease recurrence
5 days ago · New breast cancer drug slashes risk of disease recurrence Roche is hailing the trial as the most significant advance in hormonal treatment for the disease Maggie Fick …
Novel endocrine therapy reduces the risk of breast cancer …
5 days ago · The finding points to a potential new treatment option for the most common subtype of breast cancer, which accounts for roughly 70% of all cases and is most often diagnosed at …
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab …
12 hours ago · HER2-positive metastatic breast cancer is an aggressive disease driven by overexpression or amplification of HER2.8Approximately 10,000 patients are treated each …
Roche breast cancer pill cuts risk of disease recurrence by 30
LONDON, Dec 10 (Reuters) - Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine …
Pfizer details Tukysa's 1st-line data in HER2 breast cancer
5 days ago · Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current …